Bortenat 3.5MG Injection

Bortenat 3.5mg injection is anti-cancer medication used in the treatment of multiple myeloma. It contains an active ingredient is Bortezomib Injection IP that belongs to the class of medicines called antineoplastic agents (anti-cancer drugs) and is a specific type of targeted therapy known as proteasome inhibitor. It works by blocking the growth of cancer cells in the body. Strict medical prescription is needed that require careful dosing, monitoring and supervision from a healthcare professional.

Multiple myeloma

Bortenat 3.5mg injection show various side effects in some patients. Some of the symptoms are resolve on their own and some need proper medical attention. Common ones include:
● High blood pressure
● Breathlessness
● Fungal infection
● Anemia
● Itching
● Pneumonia
● Dry skin
● Gastronintestinal bleeding
● Dehydration
● Motor neuropathy

Consult the healthcare professional if the symptoms worsen and if you notice severe side effects.

Bortenat 3.5mg should be taken with or without food at the fixed time everyday to better efficacy. Do not skip, stop or overdose on the missed without consultation with a healthcare provider. It may take several weeks and months to see the beneficial results, so consistent use as prescribed is essential for achieving full therapeutic effect.

When a single plasma cells in the bone develops DNA mutation, causing it to become cancerous and multiply uncontrollably creating abnormal plasma cells and crowding out healthy blood cells that weaken bones. Bortenat Injection work directly on binding the DNA mutation which is responsible for the growth of tumor in the body. It also prevents the body from further cancer progression, supporting the body in controlling the spread of malignant cells.

• Abhilash, G. (2013). Preparation and Evaluation of Injection for the Treatment of Multiple Myeloma (Master's thesis, Rajiv Gandhi University of Health Sciences (India)).
• Byrn, S. R., Tishmack, P. A., Milton, M. J., & van de Velde, H. (2011). Analysis of two commercially available bortezomib products: differences in assay of active agent and impurity profile. AAPS PharmSciTech, 12(2), 461-467.
• Pulla, R. P., Prakash, K. V., Abhini, U. B., Maheswari, B. N., Divya, V., Shushmitha, M. V., & Ravali, V. (2017). Development and validation of bio analytical method for estimation of bortezomib in k3 EDTA human plasma using HPLC-ESI-MS/MS and its application to a bioequivalence & CME studies. British Journal of Pharmaceutical Research, 14(4), 1-17.
• LINKS, G., LINKS, A., & BOOKS, P. BORTEZOMIB, PS 341.
• Chaudhuri, S. WPS No. 813/September, 2018.